patients had to have either (a) stage 3 disease with residual tumour positive at the 123 I-or 131 I-MIBG scintigraphy at end of first-line therapy (group A), or (b) stage 4 disease partially responsive to first-line therapy with residual tumour at the level of primary tumour and/or skeleton (no more than four lesions) and/or bone marrow (only if infiltration was of minimal entity) with at least one lesion clearly uptaking 123 I-or 131 I-MIBG (group B). The cohort of 43 patients in this study (13 stage 3 and 30 stage 4) represents all the patients with these characteristics treated in our institution. This accounts for approximately one-third of the patients enrolled in the Italian protocols between 1985 and 1996 who reached partial response to first-line therapy (28 out of 76 stage 3 and 102 out of 281 stage 4 patients). In the same period we diagnosed and treated 36 stage 3 and 112 stage 4 patients aged more than 1 year.
Further eligibility criteria included recovery of haematopoiesis from previous chemotherapy, and normal renal, hepatic and thyroid functions. Parents or guardian were informed of the experimental nature of this treatment and requested to give written consent. The study was approved by the Ethical Committee of the Giannina Gaslini Children's Hospital.
Evaluation before 131 
I-MIBG therapy
Pretreatment evaluation included physical examination, complete blood cell count with platelet and differential white cell count, blood tests showing normal thyroid, kidney and liver functions, imaging studies of the primary tumour with computerized tomography and/or magnetic resonance imaging and 123 I-or 131 I-MIBG scintigraphy, measurement of tumour markers (vanillylmandelic [VMA] and homovanillic [HVA] acids in urine; ferritin, neuronspecific enolase and lactate dehydrogenase in serum) and marrow evaluation consisting of four aspirations and two trephine biopsies.
Disease evaluation to assess tumour response was performed between 3 and 6 weeks after each 131 I-MIBG course.
Evaluation of tumour response
Tumour response was defined as follows (Brodeur et al, 1993) : complete response (CR), disappearance of primary tumour and of all metastatic lesions with normalization of urine catecholamines; very good partial response (VGPR), > 90% volume reduction of the primary tumour with clearing of all measurable metastatic lesions with the exception of residual changes at skeletal scintigraphy, normalization of urine catecholamines; partial response (PR), > 50% volume reduction of the primary tumour and of all measurable metastatic lesions, residual marrow infiltration in only one site; mixed response (MR), > 50% reduction of any measurable lesion (primary or metastases) with < 50% reduction in any other and < 25% increase in any existing lesion; no response (NR), < 50% reduction but < 25% increase in any existing lesion; progressive disease (PD), increase > 25% of any measurable lesion or appearance of a new lesion(s). The isolated decrease of 131 I-MIBG uptake was not considered evidence of tumour response. Response was evaluated 4-8 weeks following each 131 I-MIBG course. The best response achieved is reported in the Results section of the article and in the Tables. Some patients underwent further improvement several months after completion of 131 I-MIBG therapy and the best status achieved is reported in the outcome.
131

I-MIBG therapy
The administered doses of 131 I-MIBG ranged from 2.5 to 5.5 GBq according to body weight: 2.5-3.7 GBq for patients weighing less than 15 kg; 3.7-4.7 GBq for patients weighing 15-20 kg; 5.5 GBq for those weighing more than 20 kg. Specific activity ranged from 1.1 to 2.8 GBq mg -1 (median 1.6). Doses were determined attempting to give at least 2000 cGy to the tumour and possibly less then 200 cGy to the whole body (Beirewaltes, 1987) .
Thyroid gland uptake of radioiodine was blocked by oral administration of iodine (2-3 mg kg -1 day -1 of iodine as Lugol's solution) given for 5 days before and 8 days after 131 Toxic effects attributable to 131 I-MIBG therapy were evaluated according to WHO criteria (WHO, 1979) . The duration of 131 I-MIBG treatment depended on tumour response and toxicity. In case of either disease improvement or stability after the first 131 I-MIBG course, additional courses up to a maximum of 5 with an interval of 4-6 weeks between courses were administered unless evidence of progressive disease was documented or excessive myelotoxicity had occurred.
I-MIBG
RESULTS
Group A consisted of 13 stage 3 disease patients who had had partial tumour response to first-line regimen. Before 131 I-MIBG therapy 11 patients underwent second-look surgery consisting of partial tumour resection in four and of a biopsy only in seven with histological evidence of viable tumour cells in all surgical specimens. At the time of entry into this study all patients but one had abnormal urinary catecholamine excretion. All showed pathological scintigraphic *I-MIBG uptake at the site of the primary.
Main patients' data including characteristics at diagnosis, interval from diagnosis to 131 was studied, and in two patients an abnormal copy number was present.
One patient received one 131 I-MIBG course, three patients received two courses, four received three courses and five received four courses. The interval between courses ranged from 4 to 8 weeks (median, 7). Two patients had partial and one had mixed response (< 25% reduction of tumour volume with return to normal of catecholamines). The disease remained stable in nine patients and progressed in one alone.
No further antitumour therapy was administered and four patients became progressively disease-free including normal *I-MIBG scan despite some 'irregularity' detected by imaging studies at level of primary tumour and interpreted as possible scar tissue. They are now alive at 47-107 months (median, 78) from diagnosis (case nos 2, 5, 6, 12). Eight patients are alive with stable disease (residual tumour persisting at imaging and MIBG scan) at 24-131 months (median, 74). Four of them underwent biopsy of the residual tumour with histological findings of ganglioneuroma in two (case nos 3, 7) and of ganglioneuroblastoma in the other two (case nos 4, 9). The only case (no. 11) who developed PD after 131 I-MIBG therapy died 9 months later. He was one of the two patients with an amplified NMYC gene. The 5-year event-free survival (EFS) of this group is 92% (± 0.07) with follow-up of 34-131 months (median, 78) ( Figure 1 ).
Group B consisted of 30 patients with stage 4 disease who achieved partial response with first-line therapy. Twenty-one received 131 I-MIBG therapy within 2 months from completion of their chemotherapy protocol ending in a course of myeloablative therapy, while in the remaining nine patients 131 I-MIBG therapy was not preceded by myeloablative therapy due to (a) inoperable primary tumour (five patients), (b) bone marrow infiltration by tumour preventing autologous stem cell harvest (two patients), and (c) lack of adequate harvest (two patients). Scintigraphy performed before 131 I-MIBG therapy was positive at one site in 11 patients (at level of primary in ten, a unique bone lesion in one), two sites in five, three or more sites in 14.
Main patient data are summarized in Table 2 . Five patients received one 131 I-MIBG course of therapy, 13 received two courses, nine received three courses, two received four courses and one received five courses. Intervals between courses ranged from 4 to 16 weeks (median, 7).
One patient (case no. 29) achieved CR (clearing of two bone lesions) and is presently alive disease-free 50 months later. Eleven patients had PR involving the primary tumour (the only tumour lesion) in four cases (nos 1, 4, 5, 7), a single bone lesion in one case (case no. 28), bone marrow in one (case no. 30), bone marrow plus primary in one (case no. 22), and bone plus bone marrow and primary in three (case nos 16, 17, 23). Eight of them are alive at 36-153 months (median, 53) among whom four are in CR (case nos 1, 4, 5, 28) including case no. 1 who developed myeloid leukaemia and is presently in CR after allogeneic bone marrow graft, two cases who had no further disease change (case nos 8, 17) including case no. 17 who developed myeloid leukaemia and is still alive after 14 months and one (case no. 30) who is alive with PD. Fourteen patients did not respond. Among them one is alive with PD at 24 months (case no. 25) and five are alive with stable disease (case nos 6, 8, 10, 19, 26) at 22-88 months (median, 42) from diagnosis, while the remaining nine patients died, among whom seven of disease at 13-21 months (median, 20) and two of toxicity.
The last four patients (case nos 13, 14, 24, 27) experienced early PD and died within a few months. The 5-year EFS of this group is 40% (± 0.08) (Figure 1 ).
Patients having a single tumour lesion positive at *I-MIBG scan had better chance of survival with eight out of 11 surviving, four of whom in CR. Of the four patients with two positive lesions, two are presently alive with non-progressive disease and one is alive in CR. Of the 14 with three or more *I-MIBG-positive lesions, only three are currently alive among whom two with stable disease and one with PD.
Bone marrow infiltration at time of 131 I-MIBG therapy was prognostically unfavourable, since only three of 11 such patients are presently alive, one with stable disease and two with PD.
Of the 18 patients with normal NMYC copy number, 11 are alive; out of four patients with amplified NMYC only one survives, and two out of seven patients not evaluated for this gene survive.
The majority of patients who responded to 131 I-MIBG therapy and survive are those who received 131 I-MIBG after myeloablative therapy. In fact, out of 21 such patients nine responded (one CR, eight PR), nine had no disease change (one died of toxicity and eight progressed) and three developed progressive disease. On the contrary, in the group of nine patients who were not eligible for such a therapy only one responded, although a total of four are alive with stable disease.
Toxicity
Acute toxicity
No noticeable reaction was registered during or shortly after the administration of 131 I-MIBG courses.
Haematological toxicity (Table 3) Among the group A patients the main toxicity of this type attributable to 131 I-MIBG was thrombocytopenia. However, out of 32 evaluable courses only two patients had grade 4 thrombocytopenia and three others had grade 3 toxicity which did not worsen with subsequent courses. Six patients, for a total of 24 courses, manifested no haematological toxicity.
In group B patients 58/72 courses were evaluable. Only one patient had no marrow toxicity. Grade 4 thrombocytopenia occurred after 19 course* grade 3 leukopenia occurred after 18 courses. None of the 21 patients who received therapeutic 131 I-MIBG after myeloablative chemotherapy and autologous stem cell rescue had grade 4 haematological toxicity, although 12 developed grade 3 and seven grade 2 thrombocytopenia, which was often long-lasting (2-7 months; median 5). Both thrombocytopenia and leukopenia occurred in most cases 3-5 weeks following administration of 131 I-MIBG therapy. Lymphocytopenia below 1 × 10 9 L -1 was found only after nine of 50 evaluable courses and appeared earlier (7-10 days after 131 I-MIBG infusion) than other haematological toxicities.
Other toxicities
One stage 4 disease patient (case no. 21) treated with megatherapy and autologous bone marrow rescue, followed by three courses of 131 I-MIBG therapy, developed interstitial pneumopathy 1 month after the last course and died. One stage 4 patient (case no. 17) developed acute myeloid leukaemia (FAB M2) 1 year after the last (third) 131 I-MIBG course. She had previously received carboplatin for a total dose of 4.4 g m -2 , cyclophosphamide for 14.4 g m -2 , etoposide for 1.5 mg m -2 and melphalan for 140 mg m -2 , plus 27 Gy radiation therapy to the primary tumour site. Another stage 4 disease patient (case no. 1) who had received 1.8 g m -2 of peptichemio, 600 mg m -2 of cisplatin and only one course of 131 I-MIBG, developed myeloid leukaemia 6 years later, which was successfully treated by an unrelated marrow graft. This patient is presently alive disease-free 12 years after the initial diagnosis.
Twenty-one patients showed compensated hypothyroidism (high thyroid-stimulating hormone plasma level with normal T 3 and T 4 values). Thyroid abnormalities appeared between 1 and 44 months (median, 12) after the first dose of 131 I-MIBG. Subsequently, 15 patients developed overt hypothyroidism requiring replacement treatment with L-thyroxine at 2-56 months (median, 19) after initiation of 131 I-MIBG therapy. Thyroid function remained normal in 19 patients having at least 1 year of follow-up (17-98 months, median, 45).
DISCUSSION
Long-term survival of children with inoperable or disseminated neuroblastoma diagnosed after the age of 1 year remains largely unsatisfactory mainly because current treatment commonly fails to eradicate the disease (Garaventa et al, 1993; Haase et al, 1995; Philip et al, 1997) . Thus, until innovative and more effective therapies are developed the paediatric oncologist dealing with refractory or partially responsive neuroblastoma must struggle to optimize the therapeutic tools at his disposal (Castleberry et al, 1991; Gaze et al, 1995; Leavey et al, 1997) .
When radioiodinated benzylguanidine became available for the diagnosis of neural crest-derived tumours the possibility to use it at much higher doses for therapeutic purposes brought about a great deal of interest. Both 125 I-and 131 I-labelled MIBG seemed suitable due to their different physical characteristics. The former emits short-range energy making it theoretically suitable to destroy small tumour aggregates (Buck et al, 1985) , while the long-range radiation emitted of 131 I could be more effective to induce damage of larger tumour lesions (Weber et al, 1996) . However, since residual neuroblastoma is usually not homogeneous, 125 I short-range radioactivity might miss part of the tumour and was consequently abandoned with few exceptions (Sisson et al, 1996) and the therapeutic use of radioactive MIBG has been limited to 131 I-MIBG. Initial phase I-II studies with 131 I-MIBG therapy, dating back to the late 1980s, showed good tolerance and demonstrated objective tumour responses in 20-60% of patients failing to respond to modern therapies (Italian MIBG Workshop, 1987; Schwabe et al, 1987; Klingebiel et al, 1989; Lashford et al, 1992) . In addition, significant pain relief was noticed even in patients who did not exhibit objective responses (Klingebiel et al, 1989) . Since the anti-tumour effect is dose-dependent with a maximum tolerated dose of 12 mCi kg -1 , autologous stem cell rescue has been used to allow dose escalation up to 18 mCi kg -1 (Matthay et al, 1998 ). Lastly, attempts are being made to evaluate whether 131 I-MIBG given as front-line therapy may improve the outcome of these patients without causing excessive toxicity (Van Hasselt et al, 1996; Mastrangelo et al, 1998) . No prospective study has been carried out so far to the true potential value of MIBG therapy and to identify the group of patients who may profit best from this treatment modality. The difficulties in design such studies include the rarity of neuroblastoma, the fact that many centres do not possess the facilities to deliver the treatment to young patients, the high cost of the drug and, not least, the psychological burden of keeping patient in a radiation protected environment with limited parental contact extended for several days.
In a previous study we reported on 31 patients treated after relapse or progression: the rate and degree of responses were lower in the presence of bulky disease, a high number of MIBG-positive lesions, long duration of previous therapy and overt bone marrow infiltration (Garaventa et al, 1991) .
In the present study we administered 131 I-MIBG as therapy to children with high-risk neuroblastoma who responded to first-line therapy without achieving CR, provided that the residual primary tumour and/or metastase(s) were clearly uptaking MIBG. Our objective was to increase knowledge on toxicity of repeated cycles and the possibly to improve the outcome of these children. Our results indicate that stage 3 disease patients did benefit from this treatment. Despite the fact that only two out of 13 of them had a greater than 50% decrease of the residual primary tumour at shortterm evaluation after completion of 131 I-MIBG therapy, two others later experienced a progressive decrease in tumour size until its disappearance without receiving further anti-tumour therapy. The disease has remained stable for a median of 75 months in eight other patients. Four of these eight patients eventually underwent biopsy of the residual tumour, which turned out to be ganglioneuroma in two cases and ganglioneuroblastoma, with marked evidence of differentiation in the other two. The disease progressed in only one patient after 131 I-MIBG therapy. It is of interest that this patient had abnormal MYCN gene copy number, although a similar patient is a long survivor. Presently, 12 out of 13 patients are alive either disease-free or with stable disease with an observation period of several years in most cases (Figure 1) .
Since several authors have reported that incomplete tumour excision in stage 3 disease is associated with a worse survival rate (Garaventa et al, 1993; Haase et al, 1995; Powis et al, 1996) , we believe that our results should be considered worthy of interest despite the fact that only one of our long-term survivors had amplification of MYCN gene.
The possible benefit of 131 I-MIBG therapy for stage 4 disease patients is more difficult to prove in this study. Among 30 such patients only one achieved a CR and survives. However, ten other patients experienced a PR and six of them are alive. No tumour change was seen in 15 patients, six of whom are alive despite the absence of additional treatment. Four patients developed early progression and died. Tumour response and outcome correlated with the extent of the disease at the time of 131 I-MIBG therapy. In fact, of 11 patients with a single positive lesion at 123 I-MIBG scintigraphy eight survive with stable disease, while of 19 with two or more positive lesions only five survive. This last group includes 12 patients with bone marrow involvement of whom only two survive without tumour progression. Twenty-one of the 30 stage 4 disease patients received therapeutic 131 I-MIBG within 3 months from myeloablative therapy. Although we expected severe and long-lasting haematological toxicity in these patients, they tolerated the radioiodinated treatment surprisingly well. In particular no severe haemorrhagic episodes were recorded, though three patients required several platelet transfusions.
However, important non-haematological toxicity which was not encountered in stage 3 disease, did occur in stage 4, possibly due to the overall greater amount of chemotherapy usually given to these patients as well as occasional irradiation to large proportions of the bone marrow and skeleton. One example was the early occurrence of fatal interstitial pneumonia that one patient developed within 2 months after the last 131 I-MIBG therapy course. The precocity of this complication suggests that the elevated concentration of the radioactive compound in the pulmonary bloodstream during 131 I-MIBG therapy may aggravate a pre-existing immune deficiency favouring the growth of opportunistic micro-organisms. This hypothesis is confirmed by the increased risk of pneumopathy reported in lymphoma patients treated with 131 I-charged monoclonal antibodies (Press et al, 1995) . According to these authors, after bone marrow, the organs which are most likely to develop toxicity from radioiodinated therapy are the lungs. This should therefore be taken into consideration when planning doses and duration of this type of treatment. Even more concern raises the early occurrence of leukaemia in two out of 30 stage 4 disease patients since it could represent the result of a combined chemo-radiotherapeutic effect on bone marrow precursor cells. A similar case has recently been reported in a series of 30 children enrolled in a therapeutic 131 I-MIBG dosefinding study (Matthay et al, 1998) . If the risk of secondary leukaemia in neuroblastoma patients subjected to 131 I-MIBG therapy proved true, then the limits of this treatment would have to be more clearly defined. Subclinical hypothyroidism was frequent in our series. Statistical analysis to determine the role of factors such as age, numbers and doses of 131 I-MIBG courses could not be performed due to the small number of cases. Compliance to thyroid blockade is a critical point, however, although greater attention will be paid to minimize this complication in the future and a close follow-up of thyroid status is necessary. Few patients required chronic substitutive therapy and no significant impact on the quality of life was reported.
In conclusion, our data suggest that 131 I-MIBG therapy may provide additional anti-tumour effects in stage 3 neuroblastoma with residual disease after first-line therapy and this may translate into an overall improved outcome. This favourable result has been reached with the only side-effects being tolerable haematological and thyroid toxicity. In our opinion, the fact that 12 out of 13 such patients are alive could justify a prospective study of 131 I-MIBG therapy in this particular subset of patients. 131 I-MIBG exhibited antitumour activity in approximately one-third of stage 4 patients. Interestingly enough, the haematological toxicity of this treatment was of moderate entity even for patients who had previously received myeloablative therapy. Overall, our results suggest that the addition of 131 I-MIBG at therapeutic dosages to the conventional regimens for high-risk neuroblastoma may implement tumour response in some patients and this might translate in better chance of cure for some of them. Controlled clinical trials should be considered to define the true potential of this new therapeutic tool. However, since trials aiming to respond such an important question would imply the long lasting commitment of highly specialized centres and a potential severe toxicity the cost-benefit ratio of such a study deserves to be carefully eveluated.
